Robert G. Luo

home / authors / robert-g-luo

Robert G. Luo is a scientific director, at Downstream Process Development, BioPharma R&D, GlaxoSmithKline, King of Prussia, Pennsylvania 19406.

Articles

Molecular model of antibody taking part in immune defense. Molecule of immunoglobulin, 3D illustration | Image Credit: © Dr_Microbe - Stock.Adobe.com

Fouling Mechanisms of Filters During the Harvest Development of Monoclonal Antibody Therapeutics with Intensified Upstream Processes—Part 2

Stijn H. S. Koshari ;Hong Zhang;Antonio Ubiera;Robert G. Luo

March 2nd 2024

The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.

A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render| ©Naeblys - stock.adobe.com

Fouling Mechanisms of Filters During the Harvest Development of Monoclonal Antibody Therapeutics with Intensified Upstream Processes—Part 1

Stijn H. S. Koshari ;Hong Zhang;Antonio Ubiera;Robert G. Luo

February 2nd 2024

The authors present a methodology to assess the contribution of individual filters to overall capacity of the direct filtration train, and elucidate how capacity is affected by characteristics of the cell culture broth and process parameters, including for enhanced upstream processes such as those incorporating high cell density perfusion.